Senior leaders in health economics and market access now confront a crowded agenda of fiscal pressure, scarce workforce capacity and ever more complex therapies. This reflection interprets the latest mapping of HEOR strategic priorities as a brief for executives who must convert new signals into coherent pricing strategies, reimbursement decisions and system-level resource choices. The intent is not to restate a trends list, but to advise leadership on what the findings imply for value assessment, budget impact and long-term sustainability.

A Condensed Context for Executive Judgement

The biennial horizon scan from ISPOR ranks artificial intelligence first, real-world evidence second and value-based healthcare third, with drug pricing, innovative therapies, patient centricity, the relevance of the discipline, health technology assessment, value measurement and digital health completing the set. Member input and curation by the Health Science Policy Council shaped the order. Artificial intelligence has moved to the top because large language models and machine learning already compress literature review, data structuring and prediction into short cycle times, while still requiring firm human oversight to catch fabricated citations and other quality failures. Real-world evidence remains central as regulators expand its use; the European Medicines Agency has reported a marked rise in studies, and emulation work has shown that randomised trials can be mirrored with real-world data when methods are sound. Value-based healthcare enters the ranking because volume-driven payment can no longer absorb global cost and labour constraints.

Reading the Technology and Evidence Shift

When algorithms draft reviews and build models at speed, the scarce skill inside health economics teams becomes governance: source verification, bias checks and translation of outputs into payer-relevant metrics. Policies and checklists that test whether machine learning adds genuine value over classical methods therefore belong in standard operating practice, not in optional annexes. The same logic applies to real-world data. Disparate repositories only support reimbursement decisions when protocols disclose design, data sources and analytic choices in advance. Templates that improve reproducibility have already influenced guidance from European and US authorities, including coverage pathways under CMS. Firms that treat transparency as a late-stage publication task will find dossiers rejected or heavily discounted in negotiation.

Value-based healthcare pushes the same discipline earlier still. Payment linked to outcomes forces manufacturers and assessors to quantify nursing time, storage, wastage and throughput at the moment of adoption. Those implementation burdens are opportunity costs; ignoring them distorts system dynamics and inflates apparent value. Cross-country work on outcome standards helps, yet alignment of hospital, clinician and manufacturer incentives remains the harder operational task.

Pricing Strategies, Access and Budget Impact

Drug pricing pressure now shapes almost every launch plan. Governments move from passive reimbursement toward direct negotiation, joint procurement and potential wider use of international reference points. In that climate, value-based pricing is less a slogan than a practical menu: financial risk contracts, outcomes-based agreements, mortgage-style spreads, subscription models, indication-specific prices and volume arrangements. Each option rests on credible measurement infrastructure. Where data systems and assessment capacity are mature, flexible contracts multiply; where they are weak, access stalls and budget impact becomes a blunt affordability veto.

Innovative therapies expose the tension most clearly. Pipelines remain weighted toward rare conditions, while assessors seek evidence beyond the regulatory package and research incentives face simultaneous strain from price regulation and a geographic shift in trial activity. Managed entry arrangements can convert large one-off costs into performance-linked flows, provided HTA bodies and payers share methods for real-time evaluation. Policy implications extend across borders: if large markets adopt reference pricing more aggressively, external effects on list prices and confidential discounts elsewhere will follow. Health economics groups must therefore model not only domestic budget impact but second-order effects on global launch sequencing and differential access.

Patient-generated data and digital tools add further weight to HEOR strategic priorities. Regulators have issued clearer expectations on patient-experience evidence, and wearables can supply continuous endpoints that matter for chronic as well as rare disease populations. Whole-health concepts widen value measurement toward financial security, housing and environmental factors, which in turn lengthens relevant time horizons and pulls multi-sector costs into scope. Digital therapeutics and virtual models can support synthetic controls and remote monitoring, yet they also demand explicit real-world evidence standards for quality, analysis and reporting before they inform pricing strategies or coverage.

Implications for System Dynamics and Policy Design

Taken together, these threads reset how systems allocate resource. Artificial intelligence multiplies analytic capacity only when validation is routine. Real-world evidence reduces uncertainty only when availability, quality and transparency move in step. Value-based payment contains expenditure only when outcome sets and implementation costs enter the dossier early. For low- and middle-income settings, constrained HTA capacity makes cross-border collaboration and shared tools especially material; joint clinical assessment models in Europe illustrate one path, while managed access protocols show how oversight and budgetary certainty can coexist with earlier patient entry.

The relevance of the discipline itself is now an explicit leadership issue. Payers, providers, regulators and policy teams face competing objectives and noisy data. Structured economic and outcomes insight remains one of the few instruments that can discipline reimbursement decisions without defaulting to crude price cuts that freeze innovation. That places a duty on HEOR functions to speak in the language of budget holders and service managers, not solely in technical appendices.

Actionable Guidance for Decision-Makers

Market access directors should embed AI quality control and real-world protocol standards into evidence plans from mid-stage development, so that launch dossiers already meet the transparency expectations of major agencies. Pricing strategists should pre-build indication- and outcome-linked contract options, with clear data flows for reconciliation of budget impact. HTA organisations and payers should extend collaboration on joint assessment methods, managed entry designs and selective whole-health metrics without diluting methodological rigour. Health-system policymakers should pair payment reform with investment in interoperable registries and outcome infrastructure; price regulation alone will not deliver sustainable system dynamics. Manufacturers ought to treat regulators and payers as dual audiences from the outset, quantifying system burden and patient-centred endpoints beside classical efficacy.

Boards can usefully test every major asset against a short set of questions:

• Does the evidence package satisfy reproducibility norms?
• Have implementation costs been costed?
• Is there a workable value-based pricing path that payers can administer?
• What is the multi-year budget impact under realistic uptake?
• How do policy implications in one region cascade to others?

Disciplined answers to those questions convert trend awareness into operational advantage.

In Closing

The lasting message is that HEOR strategic priorities now function as an operating framework for decisions under constraint. Technology and data will enlarge capacity only inside robust governance. Pricing and reimbursement reforms will protect patients and budgets only when measurement and incentives align. Further method work on whole-health valuation, practical AI assurance inside assessment workflows, and scalable entry agreements for high-cost one-off therapies remains essential. Leaders who treat the agenda as an integrated programme, rather than a set of parallel topics, stand the best chance of securing both fiscal control and continued therapeutic progress.

This reflection draws on the ISPOR 2026-2027 Top 10 HEOR Trends report (https://www.ispor.org).

Frequently Asked Questions

What exactly are HEOR strategic priorities in today’s healthcare landscape?

HEOR strategic priorities centre on using health economics and outcomes research to guide pricing, reimbursement and resource allocation amid rising costs, complex therapies and workforce shortages. They emphasise governance of AI tools, transparent real-world evidence and value-based payment models that balance innovation with system sustainability.

How do HEOR strategic priorities influence drug pricing and market access decisions?

They shape practical pricing approaches such as outcomes-based agreements and indication-specific pricing by requiring strong data infrastructure. When evidence meets transparency standards, flexible contracts become feasible; otherwise, access can stall and budgets face stricter affordability checks.

Why should executives pay attention to HEOR strategic priorities now?

These priorities act as an integrated decision framework that turns emerging trends like AI and real-world evidence into actionable steps for budget impact modelling, cross-border policy effects and long-term system resilience, helping leaders avoid crude cost cuts while supporting therapeutic progress.